Medication Regimen for Stable Angina
For patients with stable angina, initiate aspirin, a beta-blocker, a statin, and an ACE inhibitor as foundational therapy to prevent MI and death, with sublingual nitroglycerin for acute symptom relief. 1
Core Medications to Prevent MI and Death (Level A Evidence)
All patients should receive:
- Aspirin (or clopidogrel if aspirin absolutely contraindicated) 1
- Beta-blocker - particularly critical if prior MI (Level A), but also recommended without prior MI (Level B) 1
- Statin therapy - targeting LDL <100 mg/dL 1
- ACE inhibitor - especially beneficial in patients with diabetes, LV dysfunction, or documented CAD 1
These four medications form the backbone of therapy because they reduce mortality and prevent cardiovascular events, not just symptoms.
Symptom Relief Medications
First-Line for Immediate Relief
- Sublingual nitroglycerin or nitroglycerin spray for acute anginal episodes (Level B) 1
First-Line for Chronic Symptom Control
Beta-blockers are the preferred initial antianginal agent because they provide both symptom relief AND mortality benefit, particularly in post-MI patients 1, 2.
Specific beta-blocker options with dosing 3:
- Metoprolol: 50-200 mg twice daily (beta-1 selective)
- Atenolol: 50-200 mg once daily (beta-1 selective)
- Bisoprolol: 10 mg once daily (beta-1 selective)
- Carvedilol: 6.25 mg twice daily, uptitrated to maximum 25 mg twice daily (combined alpha/beta blocker)
Beta-1 selective agents (metoprolol, atenolol, bisoprolol) are preferred as they have fewer side effects 3, 4. Avoid beta-blockers with intrinsic sympathomimetic activity 3.
When Beta-Blockers Are Contraindicated or Not Tolerated
If beta-blockers cannot be used, substitute with long-acting calcium channel blockers OR long-acting nitrates (Level B) 1.
Calcium Channel Blocker Options
Long-acting dihydropyridines are preferred for maintenance therapy due to sustained 24-hour effects 1:
- Amlodipine is specifically recommended (Level A evidence in heart failure patients) 4
- Felodipine ER: 10 mg once daily 5
Critical warning: Avoid short-acting dihydropyridine calcium antagonists (like immediate-release nifedipine) as they increase adverse cardiac events 1.
Non-dihydropyridine CCBs (verapamil, diltiazem) should NOT be used in patients with heart failure or LV systolic dysfunction due to negative inotropic effects 4.
Long-Acting Nitrate Options
- Oral or transcutaneous nitrates (Level A evidence for safety in heart failure) 4
- Ensure nitrate-free intervals to prevent tolerance 1
Newer Alternatives for Beta-Blocker Intolerance
The 2012 ESC guidelines provide additional options 4:
- Ivabradine (Level A) - for patients in sinus rhythm who cannot tolerate beta-blockers
- Ranolazine (Level C) - effective antianginal but safety in heart failure uncertain
- Nicorandil (Level C) - effective antianginal but safety in heart failure uncertain
Refractory Symptoms: Combination Therapy
If symptoms persist on beta-blocker monotherapy, add a long-acting calcium channel blocker (dihydropyridine) OR long-acting nitrate (Level B) 1.
Preferred combination: Beta-blocker + dihydropyridine CCB (like amlodipine) 1, 2
Second-Line Add-On Options for Refractory Angina
When two-drug therapy is insufficient, the 2024 ESC guidelines recommend 2:
- Long-acting nitrates
- Ranolazine
- Ivabradine (Class I, Level A when added to beta-blocker) 4
- Trimetazidine
- Nicorandil
Important: The 2012 ESC guidelines specifically recommend ivabradine, nitrates, and amlodipine as Class I (Level A) additions when angina persists despite beta-blocker therapy 4.
Combinations to AVOID
- Do NOT combine ivabradine, ranolazine, and nicorandil together (unknown safety) 4
- Do NOT combine nicorandil with nitrates (lack of additional efficacy) 4
- Do NOT use diltiazem or verapamil in heart failure patients 4
Medications to AVOID
Never use 1:
- Dipyridamole (Level B)
- Chelation therapy (Level B)
Clinical Pearls and Contraindications
Beta-blocker contraindications 3:
- Marked first-degree AV block (PR >0.24s)
- Second or third-degree AV block without pacemaker
- Active asthma
- Severe LV dysfunction with acute heart failure signs
- Sinus bradycardia (<50 bpm)
- Hypotension (SBP <90 mmHg)
- High risk for cardiogenic shock
For COPD patients: Beta-blockers are NOT contraindicated, but use beta-1 selective agents (bisoprolol, metoprolol succinate, or nebivolol) 4.
Initiate beta-blockers orally within first 24 hours in stable patients; avoid intravenous beta-blockers in early management due to shock risk 3.
Algorithm for Refractory Symptoms
Step 1: Beta-blocker (or CCB/nitrate if contraindicated)
Step 2: Add dihydropyridine CCB, long-acting nitrate, or ivabradine
Step 3: Consider third antianginal agent OR coronary revascularization 4
Coronary revascularization is recommended (Class I, Level A) when angina persists despite two antianginal drugs 4.